BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24508617)

  • 1. Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study.
    Giannetti P; Politis M; Su P; Turkheimer F; Malik O; Keihaninejad S; Wu K; Reynolds R; Nicholas R; Piccini P
    Neurobiol Dis; 2014 May; 65():203-10. PubMed ID: 24508617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome.
    Giannetti P; Politis M; Su P; Turkheimer FE; Malik O; Keihaninejad S; Wu K; Waldman A; Reynolds R; Nicholas R; Piccini P
    Brain; 2015 Jan; 138(Pt 1):110-9. PubMed ID: 25416179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195.
    Rissanen E; Tuisku J; Rokka J; Paavilainen T; Parkkola R; Rinne JO; Airas L
    J Nucl Med; 2014 Jun; 55(6):939-44. PubMed ID: 24711650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
    Politis M; Giannetti P; Su P; Turkheimer F; Keihaninejad S; Wu K; Waldman A; Malik O; Matthews PM; Reynolds R; Nicholas R; Piccini P
    Neurology; 2012 Aug; 79(6):523-30. PubMed ID: 22764258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
    Kaunzner UW; Kang Y; Zhang S; Morris E; Yao Y; Pandya S; Hurtado Rua SM; Park C; Gillen KM; Nguyen TD; Wang Y; Pitt D; Gauthier SA
    Brain; 2019 Jan; 142(1):133-145. PubMed ID: 30561514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
    Sucksdorff M; Matilainen M; Tuisku J; Polvinen E; Vuorimaa A; Rokka J; Nylund M; Rissanen E; Airas L
    Brain; 2020 Dec; 143(11):3318-3330. PubMed ID: 33006604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis.
    Sucksdorff M; Rissanen E; Tuisku J; Nuutinen S; Paavilainen T; Rokka J; Rinne J; Airas L
    J Nucl Med; 2017 Oct; 58(10):1646-1651. PubMed ID: 28336784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of "black holes".
    Lapucci C; Romano N; Schiavi S; Saitta L; Uccelli A; Boffa G; Pardini M; Signori A; Castellan L; Inglese M; Roccatagliata L
    Eur Radiol; 2020 Jul; 30(7):3843-3851. PubMed ID: 32162002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.
    Thaler C; Faizy T; Sedlacik J; Holst B; Stellmann JP; Young KL; Heesen C; Fiehler J; Siemonsen S
    PLoS One; 2015; 10(12):e0144693. PubMed ID: 26659852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.
    Banati RB; Newcombe J; Gunn RN; Cagnin A; Turkheimer F; Heppner F; Price G; Wegner F; Giovannoni G; Miller DH; Perkin GD; Smith T; Hewson AK; Bydder G; Kreutzberg GW; Jones T; Cuzner ML; Myers R
    Brain; 2000 Nov; 123 ( Pt 11)():2321-37. PubMed ID: 11050032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
    Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two different methods of image analysis for the assessment of microglial activation in patients with multiple sclerosis using (R)-[N-methyl-carbon-11]PK11195.
    Kang Y; Schlyer D; Kaunzner UW; Kuceyeski A; Kothari PJ; Gauthier SA
    PLoS One; 2018; 13(8):e0201289. PubMed ID: 30091993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study.
    Versijpt J; Debruyne JC; Van Laere KJ; De Vos F; Keppens J; Strijckmans K; Achten E; Slegers G; Dierckx RA; Korf J; De Reuck JL
    Mult Scler; 2005 Apr; 11(2):127-34. PubMed ID: 15794383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study.
    Pitombeira MS; Koole M; Campanholo KR; Souza AM; Duran FLS; Solla DJF; Mendes MF; Pereira SLA; Rimkus CM; Busatto GF; Callegaro D; Buchpiguel CA; de Paula Faria D
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4551-4566. PubMed ID: 35838758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.
    Kaunzner UW; Kang Y; Monohan E; Kothari PJ; Nealon N; Perumal J; Vartanian T; Kuceyeski A; Vallabhajosula S; Mozley PD; Riley CS; Newman SM; Gauthier SA
    Mult Scler Relat Disord; 2017 Jul; 15():27-33. PubMed ID: 28641769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET.
    Nylund M; Sucksdorff M; Matilainen M; Polvinen E; Tuisku J; Airas L
    Brain Commun; 2022 Feb; 4(1):fcab301. PubMed ID: 34993478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglial activation correlates with severity in Huntington disease: a clinical and PET study.
    Pavese N; Gerhard A; Tai YF; Ho AK; Turkheimer F; Barker RA; Brooks DJ; Piccini P
    Neurology; 2006 Jun; 66(11):1638-43. PubMed ID: 16769933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS).
    Barkhof F
    Mult Scler; 1999 Aug; 5(4):283-6. PubMed ID: 10467389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis.
    Nutma E; Stephenson JA; Gorter RP; de Bruin J; Boucherie DM; Donat CK; Breur M; van der Valk P; Matthews PM; Owen DR; Amor S
    Brain; 2019 Nov; 142(11):3440-3455. PubMed ID: 31578541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
    Datta G; Colasanti A; Rabiner EA; Gunn RN; Malik O; Ciccarelli O; Nicholas R; Van Vlierberghe E; Van Hecke W; Searle G; Santos-Ribeiro A; Matthews PM
    Brain; 2017 Nov; 140(11):2927-2938. PubMed ID: 29053775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.